Fig. 4: Kaplan-Meier showing disease-free survival in different subgroups according to chemotherapy arm. | British Journal of Cancer

Fig. 4: Kaplan-Meier showing disease-free survival in different subgroups according to chemotherapy arm.

From: The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

Fig. 4

Kaplan–Meier plots for disease-free survival in different subgroups according to chemotherapy arm (anthracycline-free vs. anthracycline-containing) of the PlanB and Success C trials (data pooled) for patients with pN2/pN3 lobular tumours (a), pN0/pN1 lobular tumours (b), pN2/pN3 ductal tumours (c), and pN2/pN3 tumours with another histological type (d). In addition to the results of the log-rank test, univariable hazard ratios and 95% confidence intervals are shown.

Back to article page